Clinical trial Recruiting at 1 site Interventional Ages 18 to 85

Neuromodulation for treating neuropathic pain and depression

Official title: Neuromodulation in Patients With Neuropathic Pain and Depression: a Cross-over Study Between Two Targets in Transcranial Magnetic Stimulation, the Primary Motor Cortex and the Dorsolateral Prefrontal Cortex.

Run by Centre Hospitalier Universitaire de Saint Etienne · NCT06129890 · Data updated 2026-11-12

This study is testing if a special brain treatment can help people with both nerve pain and depression feel better when regular pain medications haven't worked.

Quick facts

Study typeInterventional
Ages18 Years to 85 Years
SexAll
Enrollment60 (estimated)
SponsorCentre Hospitalier Universitaire de Saint Etienne
Academic / other
Locations1 site (Saint-Etienne)
StatusRecruiting
StartedApril 26, 2024
Main results expectedSeptember 2028
Study endsMarch 2029
Registry record updatedJuly 1, 2025
Trial IDNCT06129890 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals with chronic neuropathic pain and a depressive episode who have not responded adequately to conventional treatments.

Probably not a fit

Patients with contraindications to rTMS or those involved in litigation related to industrial accidents may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project investigates the effects of high-frequency repetitive transcranial magnetic stimulation (rTMS) on patients suffering from both neuropathic pain and depression. It employs a cross-over design where participants will undergo four sessions of rTMS targeting either the primary motor cortex (M1) or the dorsolateral prefrontal cortex (DLPFC), followed by a wash-out period and then sessions targeting the alternate site. The study aims to assess the efficacy of DLPFC rTMS in alleviating neuropathic pain while also evaluating changes in mood, quality of life, and pain catastrophizing. The study is designed for patients who have not found relief from standard pain medications.

Why it matters

Potential benefit: If successful, this approach could provide a novel treatment option for patients suffering from both neuropathic pain and depression.

How similar studies have gone: While studies have shown success with rTMS for either condition separately, this specific approach for concurrent neuropathic pain and depression is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Central or peripheral neuropathic pain
* Chronic pain (present for more than 6 months) with intensity greater than or equal to 4/10 on the numerical scale
* Pain present on a daily or near-daily basis (at least 4 days a week)
* Patient not completely relieved by recommended drug treatments for first- and second-line neuropathic pain
* Stable analgesic treatment (no new treatment or dosage adjustment) for at least one month, and will not need to be modified for the duration of the study.
* Patient with a depressive episode characterized according to DSM V criteria
* Indication for motor cortex rTMS by a neurologist
* Patient can be followed for the entire duration of the study
* Patient having received informed consent to participate in the study, and having co-signed a consent form with the investigator
* Member or beneficiary of a social security scheme

Exclusion Criteria:

* Industrial accident or litigation
* Contraindication to rTMS or MRI (seismotherapy treatment since the previous month; epilepsy and/or history of epilepsy; history of head trauma; neurosurgical lesion; intracranial hypertension; intracerebral metal clip; piercing; pacemaker; insulin pump; metal prosthesis; pregnant or breast-feeding woman; claustrophobia)
* Drug or psychoactive substance abuse
* Neuropathic pain in the context of a progressive pathology (HIV, cancer, systemic disease disease)
* Presence of other pain more severe than that justifying inclusion
* Patient unable to understand informed consent
* Patient unwilling or unable to stop treatments prohibited during the study
* Patient participating in another research protocol involving a drug within the 30 days prior to inclusion
* Patient deprived of liberty or under legal protection (guardianship, curatorship, safeguard of justice safeguard, family safeguard)
* Minor patient

Where it's running

  • CHU de Saint-Etienne
    Saint-Etienne, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.